| アブストラクト | BACKGROUND: Mefloquine belongs to the priority chemoprophylaxis drugs for travelers to malaria endemic regions. We aimed to assess the prescribing patterns for mefloquine and other antimalarials. METHODS: We conducted a descriptive drug utilization study using the U.K. Clinical Practice Research Datalink (CPRD). We assessed characteristics of individuals with a first-time antimalarial prescription for mefloquine, atovaquone/proguanil, chloroquine and/or proguanil, or doxycycline between 2001 and 2012. RESULTS: Of 165,218 individuals with a first-time antimalarial prescription, 108,344 (65.6%), 25,294 (15.3%), 23,195 (14.0%), and 8385 (5.1%) were prescribed atovaquone/proguanil, mefloquine, doxycycline, and chloroquine and/or proguanil, respectively. Among mefloquine users, 7.5% had a history of a neuropsychiatric disorder (versus 12.6%-13.7% among other antimalarial users) and 0.04% had a history of severe liver disease (versus 0.04%-0.1% among other antimalarial users). A total of 19.4% mefloquine users were children younger than 12 years (versus 0.4%-15.8% among other antimalarials), and 1.3% pregnant or postpartum women (versus 0.4%-1.4% among users of other antimalarials). CONCLUSIONS: The most frequently prescribed antimalarial chemoprophylaxis was atovaquone/proguanil. Mefloquine was occasionally prescribed for patients with comorbidities listed as contraindications, but most practitioners observed contraindications. Mefloquine was often prescribed for children and pregnant women. |
|---|
| ジャーナル名 | Travel medicine and infectious disease |
|---|
| Pubmed追加日 | 2014/6/18 |
|---|
| 投稿者 | Bloechliger, Marlene; Schlagenhauf, Patricia; Toovey, Stephen; Schnetzler, Gabriel; Tatt, Iain; Tomianovic, Danitza; Jick, Susan S; Meier, Christoph R |
|---|
| 組織名 | Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy & Epidemiology,;Department of Pharmaceutical Sciences, University Basel, Switzerland. Electronic;address: Marlene.Bloechliger@usb.ch.;University of Zurich Centre for Travel Medicine, Institute for Social and;Preventive Medicine, Zurich, Switzerland. Electronic address: pat@ifspm.uzh.ch.;Division of Infection and Immunity, Royal Free and University College Medical;School, Academic Centre for Travel Medicine and Vaccines, London, UK. Electronic;address: malaria@sunrise.ch.;F.Hoffmann-La Roche Ltd., Basel, Switzerland. Electronic address:;gabriel.schnetzler@roche.com.;iain.tatt@roche.com.;danitza.tomianovic@roche.com.;Boston Collaborative Drug Surveillance Program, Boston University School of;Public Health, Lexington, MA, United States. Electronic address: sjick@bu.edu.;Department of Pharmaceutical Sciences, University Basel, Switzerland; Boston;Collaborative Drug Surveillance Program, Boston University School of Public;Health, Lexington, MA, United States; Hospital Pharmacy, University Hospital;Basel, Switzerland. Electronic address: Christoph.Meier@usb.ch. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/24934849/ |
|---|
